Profile picture
, 4 tweets, 8 min read
My Authors
Read all threads
Good review of natural killer (NK) cells for #cancer immunotherapy from @NatRevDrugDisc: nature.com/articles/s4157…

#CellTherapy $TAK $FATE $NK @CellMedica & Century Therapeutics
@NatRevDrugDisc @CellMedica A Ph 1/2 study from @MDAndersonNews showed promising clinical data of HLA-mismatched anti-CD19 CAR-NK #CellTherapy in NHL/CLL #cancer patients (n=11): 73% ORR & 64% CR(!)

@NEJM paper: nejm.org/doi/full/10.10…

$TAK has licensed this product. Competitively relevant to $FATE.
@NatRevDrugDisc @CellMedica @MDAndersonNews @NEJM $GILD Gilead, Kite and oNKo-innate announced a research collaboration to discover cancer immunotherapies focused on natural killer (NK) cells.

Gilead will pay an undisclosed upfront and milestones. $KITE @oNKo_innate

Relevant to $FATE $JNJ $TAK $NK

gilead.com/news-and-press…
@NatRevDrugDisc @CellMedica @MDAndersonNews @NEJM @oNKo_innate New @NatureRevCancer review on the cancer-NK cell immunity cycle and a review of currently known targets.

Paper: nature.com/articles/s4156…
Missing some Tweet in this thread? You can try to force a refresh.

Keep Current with SY Investing

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Related hashtags

#cancer #CellTherapy

More from @syinvesting see all

Profile picture
SY Investing
@syinvesting
Here’s a closer look at TIGIT and its potential in #cancer therapy. This target is primed to gain more traction in immuno-oncology this year. (Thread below)

Key players developing anti-TIGIT therapies are $RHHBY $MRK $BMY $RCUS $ALPMY $BGNE $CGEN $SGEN $MREO $IVBXF & @iTeosTx
TIGIT is an inhibitory receptor expressed by activated T-cells, T-regs & NK cells

- Ligand for TIGIT (PVR) is expressed in multiple tumor types
- Activation suppresses T-cell activity
- Upregulated during PD-1 blockade

@Cancer_Cell paper (open access): cell.com/cancer-cell/fu…
A key TIGIT question is the role of FcƔR and antibody-dependent cell-mediated cytotoxicity (ADCC).

$RHHBY & $MRK support FcƔR ADCC benefit due to T-reg depletion & myeloid cell reprogramming. $RCUS states the opposite as this ADCC activity may also deplete T-effector & NK cells.
Read 29 tweets
Profile picture
SY Investing
@syinvesting
Excellent overview of the cell therapy landscape from Piper Jaffray

$GILD $NVS $CELG $JNJ $AMGN $ALLO $BLUE $IOVA $AUTL $SGMO $ATRA $CRSP $FATE $CLLS $NTLA $DTIL $ZIOP $MRKR $CYAD $BLCM $TCRR $ADAP $MBIO $NTGN $UMRX $MXCT $GMDA $SRNE $KDS $MDGEF $NK $ANIX $KITE $JUNO #ASGCT19
New article from @NatRevDrugDisc looks at the global #CellTherapy landscape: nature.com/articles/d4157…

Now, the global cell therapy pipeline includes 1,011 active agents, 258 more than a year ago.

#ASCO19
@NatRevDrugDisc Guggenheim highlights next-generation #CellTherapy approaches

1st gen: $ADAP $AMGN $ATRA $AUTL $BLCM $BLUE $CELG $CBMG $CYAD $FBIO $GILD $GSK $XON $IOVA $JNJ $MXCT $MDGEF $NVS $SRNE $TCRR $ZIOP

Next-gen: $ALLO $ATRA $CLLS $DTIL CYAD $BLCM $EVTCY $FATE $EDIT $RUBY $ERYP

#ASCO19
Read 4 tweets

Embed code for your website

×
Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!